Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma

INTRODUCTION: Relapsed histologically aggressive non-Hodgkin’s lymphoma (NHL) has a poor prognosis; relapsed patients who respond to second-line chemotherapy have a better outcome after BMT, while those who do not respond to second line or are unfit for BMT have a worse prognosis and new treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Bary, N, Hashem, T, Metwali, H, Abd el Ghany, A, Magied, HA, El-Herbeiny, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223995/
https://www.ncbi.nlm.nih.gov/pubmed/22276009
http://dx.doi.org/10.3332/ecancer.2009.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223995/
https://www.ncbi.nlm.nih.gov/pubmed/22276009
http://dx.doi.org/10.3332/ecancer.2009.144

Ejemplares similares